AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-305-671-0200. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization may be delayed.

Drug Requested: Furoscix® (furosemide)

MEMBER & PRESCRIBER INI	FORMATION: Authorization may be delayed if incomplete.				
Member Name:					
Member AvMed #:					
Prescriber Name:					
Prescriber Signature:					
Office Contact Name:					
Phone Number:	Fax Number:				
DEA OR NPI #:					
DRUG INFORMATION: Author	ization may be delayed if incomplete.				
Drug Form/Strength:					
	Length of Therapy:				
Diagnosis:	ICD Code:				
Weight:	Date:				
Quantity Limit: 2 on-body infusors p	er fluid overload episode (max of 2 per fill)				
	elow all that apply. All criteria must be met for approval. To ation, including lab results, diagnostics, and/or chart notes, must be				
Initial Authorization: 6 months					
☐ Member is 18 years of age or older	r				
☐ Member has a diagnosis of New Y	ork Heart Association (NYHA) Class II or III chronic heart failure				
☐ Member is experiencing congestion	n due to fluid overload				
☐ Member does <u>NOT</u> have anuria or	hepatic cirrhosis or ascites				
☐ Member does <u>NOT</u> have a hyperse	ensitivity to furosemide or medical adhesives				
☐ Member does NOT have acute pul	monary edema				

PA Furoscix (Pharmacy)(AvMed) (Continued from previous page)

Prescriber attests,	Furoscix	will NOT	be	prescribed	for an	emergency	situation

- □ Prescriber attests the member requires a non-oral route of administration of a loop diuretic for congestion due to fluid overload in chronic heart failure
- □ Prescriber attests the member will be monitored outpatient for fluid, electrolyte, and metabolic abnormalities

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ☐ Member must have disease improvement and/or stabilization OR improvement in the slope of decline (e.g., improvement in signs/symptoms of fluid overload edema, dyspnea, rapid weight gain)
- ☐ Member has <u>NOT</u> experienced any treatment-restricting adverse effects (e.g., fluid, electrolyte, or metabolic abnormalities, worsening renal function, ototoxicity, acute urinary retention)

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

*Approved by Pharmacy and Therapeutics Committee: 2/16/2023 REVISED/UPDATED: 03/09/2023;10/26/2023